Journal of bone oncology · 2026 · 系統性回顧＋統合分析（依標題推測）
Tenosynovial giant cell tumor of the hip: a systematic review and institutional case series with Meta-analysis of recurrence and patient-reported outcomes.
髖與鼠蹊 · 腱鞘巨細胞瘤
中文閱讀摘要
髖部TGCT系統性回顧與統合分析顯示，不同手術策略復發風險無顯著差異，但人工關節置換併發症較高，術後疼痛干擾持續存在。
AI 依來源摘要整理，未經人工逐篇核對。閱讀結論前，請回溯研究族群、方法與限制。
原始摘要
Background
Tenosynovial giant cell tumors (TGCT) are rare, locally aggressive neoplasms of the synovium, most frequently affecting the knee and less commonly the hip. Due to its deep anatomy and weight-bearing function, hip TGCT may follow a distinct clinical course. This study evaluates clinical presentation, treatment outcomes, recurrence patterns, and patient-reported outcomes in hip TGCT.
Methods
A systematic literature search in PubMed, Embase, and Cochrane Library (January 2000-May 2025) identified studies including ≥5 patients with hip TGCT reporting recurrence, complications, functional outcomes or patient-reported outcomes. A random-effects meta-analysis assessed recurrence risk across treatment modalities. Additionally, 23 patients of two retrospective institutional cohorts were analyzed, including PROMIS-CAT assessment.
Results
Seventeen studies comprising 269 patients were included. The mean age was 32 years and 58% were female. At diagnosis, 48% of patients with available cartilage data demonstrated advanced degeneration (grade ≥ 3). No statistically significant differences in recurrence risk were observed between treatment strategies; arthroscopic synovectomy, open synovectomy, and total hip arthroplasty. However, comparisons were limited by heterogeneous patient selection and follow-up duration. Arthroplasty was associated with the highest complication rate (33%), primarily aseptic loosening (19%). In the institutional cohort, 21.7% experienced recurrence and 29.4% required conversion to THA. Recurrences and conversions occurred exclusively in D-TGCT. PROMIS-CAT pain interference scores remained elevated (mean T-score 63.4 ± 11.1).
Conclusion
Hip TGCT shows substantial cartilage damage at diagnosis and persistent postoperative morbidity. While recurrence rates appear comparable between surgical strategies, arthroplasty carries a higher complication burden in this predominantly young population. Prospective multicenter studies with standardized outcome reporting are required to optimize treatment strategies.
至 Europe PMC 閱讀完整來源 ↗ · 擷取日期 2026-10-19
書目、來源與全文狀態
- DOI
- 10.1016/j.jbo.2026.100769
- PMID／PMCID
- 42256642 / PMC13241937
- 作者
- van der Loos E, Meijer DT, Bramer JAM, Schreuder HWB, Verspoor FGM
- 首次發表日期
- 2026-05-25Europe PMC 提供，部分日期可能依年份或月份推定。
- 卷／期／頁碼或文章編號
- 58 ／ 期未提供 ／ 100769
- 書目來源與查核日期
- Europe PMC · 2026-10-19僅核對書目欄位與來源連結；不代表已評讀研究品質。
- 全文與授權
- 來源列有免費全文（查核 2026-10-19），未逐篇測試 PDF 下載。 來源授權標示：cc by。
可回溯引用
van der Loos E, Meijer DT, Bramer JAM, Schreuder HWB, Verspoor FGM. Tenosynovial giant cell tumor of the hip: a systematic review and institutional case series with Meta-analysis of recurrence and patient-reported outcomes. Journal of bone oncology. 2026;58:100769. PMID: 42256642. PMCID: PMC13241937. doi:10.1016/j.jbo.2026.100769
本站供教育與研究參考。單篇摘要、文體標籤與期刊影響係數不等於證據品質或個別病人的診療建議。